Report Overview

The U.S. Tumor-Infiltrating Lymphocyte Therapy Market was valued at USD 0.14 Billion in 2024 and reached USD 0.18 Billion in 2025. The market is projected to grow to USD 2.08 Billion by 2034, expanding at a CAGR of 31.2% during the forecast period from 2026 to 2034.  While The Tumor-Infiltrating Lymphocyte Therapy Market was valued at approximately USD 0.23 Billion in 2024 and reached USD 0.30 Billion in 2025. The market is projected to grow significantly, reaching USD 3.50 Billion by 2034, expanding at a CAGR of 31.4% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 3.20 Billion over the analysis period. Demand is anchored to a single commercial product through 2025, with multiple late-stage candidates expected to broaden the tumor-infiltrating lymphocyte therapy market during the second half of the decade.

The accelerated approval of Amtagvi (lifileucel) by the U.S. Food and Drug Administration on 16 February 2024 created the first reimbursable revenue line for autologous tumor-infiltrating lymphocyte therapy in any solid tumor. Iovance Biotherapeutics priced the one-time treatment at a wholesale acquisition cost of USD 515,000 per patient, anchoring per-patient economics for the category. Iovance posted USD 58 million in third-quarter 2025 Amtagvi product revenue, drawn from a network of more than 80 authorized treatment centers operating across roughly 40 U.S. states.

Regulatory expansion accelerated through 2025 and into early 2026. Health Canada issued a Notice of Compliance with Conditions on 18 August 2025, granting Amtagvi the first ex-U.S. marketing authorization for any solid-tumor T cell therapy. Reviews remain active with the United Kingdom Medicines and Healthcare products Regulatory Agency and Australia’s Therapeutic Goods Administration, with Iovance guiding to first-half 2026 decisions in both jurisdictions. The European marketing application was withdrawn on 22 July 2025 after misalignment with the EMA Committee for Medicinal Products for Human Use, removing near-term EU exposure from the tumor-infiltrating lymphocyte therapy market and shifting management focus to a virtual-control-arm resubmission strategy.

Pipeline depth supports the forecast. Industry analysis indicates more than 75 tumor-infiltrating lymphocyte programs are progressing across preclinical and clinical development globally, with over 100 active clinical trials on file at clinicaltrials.gov. Second-generation engineered candidates are advancing on three technical lines: membrane-bound IL-15 armored TIL (Obsidian OBX-115), CRISPR-edited dual-knockout TIL (KSQ-004EX with SOCS1 and Regnase-1 inactivation), and oncolytic-virus-paired TIL (TILT-123). The IOV-LUN-202 readout in non-squamous non-small cell lung cancer reported a 25.6% objective response rate on 3 November 2025, supporting a 2026 supplemental Biologics License Application and a second indication launch in the second half of 2027.

Manufacturing economics remain the principal constraint on market velocity. Mean vein-to-vein turnaround for Amtagvi sits near 32 days as of third-quarter 2025, and Iovance gross margin reached 43% during the same period, climbing from 31% mid-year as the Iovance Cell Therapy Center scaled. Forecasts through 2034 assume continued reduction in turnaround time, broader payer coverage outside MS-DRG 018, and label expansion into NSCLC, endometrial cancer, and frontline melanoma.

Market Definition & Scope

The tumor-infiltrating lymphocyte therapy market is defined as the worldwide commercial and clinical-development activity for adoptive cell therapies in which T cells are isolated from a patient’s resected tumor tissue, expanded ex vivo with interleukin-2, and reinfused following non-myeloablative lymphodepleting chemotherapy. The market encompasses unmodified autologous TIL products, neoantigen-selected TIL products, and gene-edited or transgene-armored engineered TIL therapies (eTIL).

The scope includes commercial revenue from approved TIL products, clinical-trial-stage spending by sponsors, contract manufacturing services dedicated to TIL expansion, and authorized-treatment-center service revenue tied to TIL administration. The scope explicitly excludes CAR-T cell therapies, T cell receptor (TCR-T) therapies, natural killer cell therapies, and TIL-derived diagnostic biomarker testing. The parent market is autologous T cell immunotherapy, of which the tumor-infiltrating lymphocyte therapy market represented approximately 4.6% of disclosed product revenue in 2025.

Key Takeaways

• Market Growth: The tumor-infiltrating lymphocyte therapy market expanded from USD 0.30 Billion in 2025 toward a forecast of USD 3.50 Billion by 2034, reflecting a CAGR of 31.4% through the analysis period.
• Segment Dominance (By Cell Source): Autologous TIL therapies captured approximately 96.5% of revenue in 2025 because every approved and late-stage candidate uses patient-derived starting material.
• Segment Dominance (By Indication): Advanced melanoma accounted for 91.2% of 2025 revenue, anchored by Amtagvi’s post-anti-PD-1 label and 102 commercial patients infused in second-quarter 2025 alone.
• Driver: A 31.5% objective response rate in registrational C-144-01 melanoma data, combined with a 43.5% durability rate beyond 12 months, has converted a 7,500-patient annual U.S. third-line melanoma pool into addressable demand.
• Restraint: A 7.5% treatment-related mortality rate observed in C-144-01, paired with hospital-only administration requirements under MS-DRG 018, limits referral conversion to roughly 60-70% of biologically eligible patients.
• Opportunity: Lifileucel’s NSCLC opportunity is roughly 7 times the melanoma opportunity per Iovance management commentary, representing approximately USD 3 to USD 4 Billion in incremental U.S. addressable revenue if approved in 2027.
• Trend: Engineered TIL adoption is climbing rapidly; the share of pipeline candidates carrying gene editing or armored cytokines reached approximately 28% in 2025, up from less than 10% in 2022.
• Regional: North America led the tumor-infiltrating lymphocyte therapy market with 71.0% share and USD 0.213 Billion in 2025, driven entirely by U.S. Amtagvi commercial uptake.

Key Insights Summary

• U.S. Amtagvi Commercial Footprint: As of November 2025, Iovance disclosed that more than 80 authorized treatment centers had been activated across nearly 40 U.S. states, placing roughly 95% of eligible melanoma patients within a two-hour travel radius of a TIL infusion site.
• NSCLC Phase 2 Readout: The IOV-LUN-202 trial reported on 3 November 2025 a 25.6% objective response rate in 39 evaluable advanced non-squamous NSCLC patients, with a 71.8% disease control rate and a median duration of response not reached at 25.4 months of follow-up.
• Health Canada Conditional Clearance: On 18 August 2025, Health Canada granted lifileucel a Notice of Compliance with Conditions for advanced melanoma after anti-PD-1 and targeted therapy, registering the first solid-tumor T cell therapy authorization in Canada.
• EMA Withdrawal: Iovance pulled the European marketing application on 22 July 2025 following CHMP discussions, with formal noting at the 15-18 September 2025 CHMP meeting; no near-term EU revenue is projected for the tumor-infiltrating lymphocyte therapy market.
• CRISPR-Engineered TIL Milestone: On 9 April 2025, KSQ Therapeutics dosed the first patient with KSQ-004EX (SOCS1 and Regnase-1 dual knockout) at MD Anderson Cancer Center, marking the first CRISPR-edited TIL product to reach clinical evaluation in solid tumors.
• Manufacturing Turnaround Compression: Iovance reported a mean vein-to-vein cycle of approximately 32 days for Amtagvi during third-quarter 2025, down from the 34-day baseline reported at FDA approval and approaching the company target of 28 days by year-end 2026.
• Pricing Anchor: Amtagvi carries a wholesale acquisition cost of USD 515,000 per single-dose treatment, slightly above autologous CAR-T benchmarks and assigned to MS-DRG 018 reimbursement under Medicare inpatient rules.

Competitive Landscape Overview

The tumor-infiltrating lymphocyte therapy market remains highly consolidated, with one commercial product and a fragmented clinical pipeline behind it. Iovance Biotherapeutics held approximately 99% of disclosed product revenue in 2025, making the top-1 share larger than the entire challenger field combined. The next four most clinically advanced sponsors (Obsidian Therapeutics, KSQ Therapeutics, Instil Bio, and Biosyngen) collectively account for less than 1% of revenue but roughly 35% of late-stage TIL pipeline volume. Competition is differentiated on three vectors: manufacturing turnaround, engineering enhancements (CRISPR knockouts, armored cytokines, oncolytic virus combinations), and indication breadth beyond melanoma.

Competitive intensity is rising on the engineered-TIL line. Obsidian’s mbIL15-armored OBX-115 is positioned as an IL-2-sparing therapy, KSQ-004EX targets superior anti-tumor functionality through dual gene knockouts, and TILT-123 pairs autologous TIL with an oncolytic adenovirus. Several mid-stage sponsors that had been visible in TIL through 2024 (Achilles Therapeutics, Lyell Immunopharma, and Turnstone Biologics) exited or paused their TIL programs through 2024-2025, removing roughly USD 250 million in committed clinical-stage spend from the field.

Competitive Landscape Matrix

Segmentation Analysis

The tumor-infiltrating lymphocyte therapy market segments along four dimensions that reflect commercial reimbursement and clinical development structure: cell source, therapy type, indication, and end-user setting. Segment shares below reflect 2025 base-year revenue and clinical-trial activity.

By Cell Source

The tumor-infiltrating lymphocyte therapy market is led by autologous TIL products, which captured 96.5% of 2025 revenue and roughly USD 0.290 Billion in absolute value. Every approved or registrational-stage TIL product on the market is autologous, including Amtagvi (lifileucel), OBX-115, and KSQ-004EX. Autologous design preserves the polyclonal antigen specificity drawn from the patient’s native anti-tumor immune response, which is the mechanistic basis for activity in heavily pretreated melanoma. Manufacturing complexity remains the principal trade-off, with vein-to-vein cycles still in the 28-35 day range across the field.

Allogeneic and donor-derived TIL approaches accounted for approximately 3.5% of 2025 revenue, reflecting research-only positioning across a small number of academic Phase 1 programs led by Cellectis and university centers. Allogeneic TIL faces the same antigen-recognition limits that have constrained allogeneic CAR-T progress in solid tumors.

By Therapy Type

Unmodified autologous TIL captured 92.0% of revenue and approximately USD 0.276 Billion in 2025, driven by Amtagvi sales and a small contribution from academic-investigator-sponsored protocols at the National Cancer Institute and MD Anderson. The category benefits from the largest evidence base, including the 5-year C-144-01 follow-up published in the Journal of Clinical Oncology in June 2025.

Engineered TIL therapies (eTIL) held approximately 8.0% of 2025 revenue but represented roughly 28% of the active clinical pipeline by program count, up from under 10% in 2022. Three sub-classes are advancing: gene-edited TIL such as KSQ-004EX with CRISPR/Cas9 inactivation of SOCS1 and Regnase-1; cytokine-armored TIL such as Obsidian’s OBX-115 carrying pharmacologically regulatable membrane-bound IL-15; and neoantigen-selected TIL such as TBio-4101 from Turnstone Biologics. Obsidian’s 2 June 2025 ASCO data showed that low-dose lymphodepletion (approximately 50% reduction in cyclophosphamide) is feasible with mbIL15 armoring, hinting at a future outpatient TIL profile that could expand the addressable patient pool.

By Indication

Melanoma anchored the tumor-infiltrating lymphocyte therapy market with 91.2% of 2025 revenue, roughly USD 0.274 Billion, driven by Amtagvi’s post-anti-PD-1 melanoma label and approximately 7,500 eligible third-line U.S. patients annually. Iovance treated 102 commercial Amtagvi patients in second-quarter 2025 alone. Real-world data presented in 2025 also showed a 60% objective response rate in the second-line setting, supporting label-expansion economics tied to the TILVANCE-301 Phase 3 confirmatory trial active at more than 75 clinical sites.

Non-small cell lung cancer accounted for approximately 4.6% of 2025 revenue, generated through Phase 2 trial activity rather than commercial sales. The IOV-LUN-202 readout in November 2025 (25.6% ORR, 71.8% disease control rate) supports a sBLA filing in 2026 and a launch in the second half of 2027. Iovance management has described the NSCLC commercial opportunity as roughly 7 times the melanoma opportunity. Cervical, head and neck, endometrial, and other gynecologic carcinomas combined for the remaining 4.2% of 2025 revenue, with the IOV-END-201 endometrial cancer trial expected to report initial data in 2026.

By End-User

Academic medical centers and dedicated cancer centers captured 76.4% of 2025 tumor-infiltrating lymphocyte therapy market revenue and approximately USD 0.229 Billion, reflecting the concentration of authorized treatment centers at top-tier oncology institutions including Stanford University, Roswell Park Cancer Institute, MD Anderson Cancer Center, and Memorial Sloan Kettering. These sites carry the surgical, ICU, and cell-therapy infrastructure required to handle the lymphodepleting regimen plus high-dose IL-2 (Proleukin) coadministration that follows TIL infusion.

Community oncology centers and specialty hospitals contributed roughly 23.6% of 2025 revenue and continue to scale; Iovance reported the first community-ATC patient infusions during third-quarter 2025. Distribution was further broadened by a specialty-pharmacy agreement with InspiroGene by McKesson. Community ATC growth is the most likely volume lever through 2027 because academic-center capacity is constrained by surgical OR scheduling and ICU bed availability.

Regional Analysis

U.S. Tumor-Infiltrating Lymphocyte Therapy Market Regional Overview

The United States is the global leader in the Tumor-Infiltrating Lymphocyte (TIL) Therapy Market, supported by its highly advanced oncology ecosystem, strong biotechnology sector, and extensive clinical research infrastructure. The country has been at the forefront of developing adoptive cell therapies, driven by increasing investments in precision oncology, favorable regulatory pathways, and a growing number of clinical trials targeting advanced solid tumors such as melanoma, cervical cancer, non-small cell lung cancer, and head and neck cancers. The presence of leading biotechnology companies, academic cancer centers, and specialized cell therapy manufacturing facilities continues to strengthen the commercialization and adoption of TIL-based therapies across the U.S. healthcare system.

Regionally, market growth is concentrated across the Northeast, Midwest, South, and West, where renowned cancer institutes, research universities, and biopharmaceutical innovation hubs are actively advancing tumor-infiltrating lymphocyte research and expanding patient access to personalized immunotherapies. Increasing collaborations between biotechnology companies, contract development and manufacturing organizations (CDMOs), and healthcare providers are accelerating improvements in cell isolation, expansion, and manufacturing technologies while reducing production timelines. Furthermore, rising investments in next-generation cell therapy platforms, expanding reimbursement support for innovative oncology treatments, and growing demand for personalized cancer therapies are expected to reinforce the long-term growth of the U.S. Tumor-Infiltrating Lymphocyte Therapy Market throughout the forecast period from 2026 to 2034.

Get More Information about this report -

Request Free Sample Report

Key Market Segment

By Cell Source

• Autologous TIL Therapy
• Allogeneic TIL Therapy

By Therapy Type

• Monotherapy
• Combination Therapy

By Indication

• Melanoma
• Lung Cancer
• Cervical Cancer
• Head & Neck Cancer
• Others

By End-User

• Hospitals
• Cancer Treatment Centers
• Research Institutes
• Others

By Regional Coverage

• US